Introduction: Cigarette smoking has recently been associated with several gastrointestinal symptoms, and smoking cessation has been recommended as a lifestyle change strategy for irritable bowel syndrome (IBS). This study assessed the prevalence of IBS in cigarette smokers based on the Rome IV criteria, the severity of nicotine dependence, and the effect of smoking cessation in smokers with IBS.
Methods: This prospective study included 371 smokers who attended smoking cessation treatment at family medicine clinics in a tertiary hospital between January and April 2019, in Turkey. Data on demographic characteristics, IBS status according to the Rome IV criteria, and Fagerström test for nicotine dependence (FTND) scores were collected during face-to-face interviews.
Results: The mean patient age was 40.7 ± 11.96 years. Out of the total patients, 29.4% were heavy smokers, and 18.1% had IBS. There was a significant difference in age (p=0.03), duration of smoking (p=0.05), FTND score (p=0.02), and sex (p<0.001) between those with and without IBS. Logistic regression analyses identified female sex as a predictor of IBS in smokers (adjusted odds ratio, AOR=1.78; 95% CI: 1.18-2.69; p=0.006). At follow-up at 1 year, IBS(+) smokers who had quit smoking showed decreased gastrointestinal symptoms (p=0.035).
Conclusions: FTND score was higher in IBS(+) smokers than in IBS(-) smokers. Smoking cessation ameliorated gastrointestinal symptoms but did not affect IBS status.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899802 | PMC |
http://dx.doi.org/10.18332/tid/145925 | DOI Listing |
Eur J Radiol
December 2024
Department of Radiology, University Medical Centre Groningen, Groningen, the Netherlands. Electronic address:
Purpose: Previous research has demonstrated improvements in CT-derived bronchial parameters in the first years after smoking cessation. This study investigates the association between longer smoking cessation duration and bronchial parameters in lung-healthy and lung-unhealthy ex-smokers from the general population.
Materials And Methods: We conducted a cross-sectional analysis using low-dose CT scans of ex-smokers from the general population with at least 10 pack-years from the ImaLife study, a sub study within the Lifelines cohort.
Asia Pac J Public Health
January 2025
Department of Dental Hygiene, College of Software and Digital Healthcare Convergence, Yonsei University, Wonju, South Korea.
This study evaluates the influence of smoking cessation policies and COVID-19 on the prevalence of smoking among Korean adolescents from 2011 to 2020. Based on the Korea Youth Risk Behavior Web-based Survey, trends in adolescent smoking behaviors were examined, including the impact of cigarette price increases, Pictorial Warning Labels (PWLs), and the onset of COVID-19. We used joinpoint regression analysis to discern annual changes in the prevalence of adolescent smokers.
View Article and Find Full Text PDFBMC Psychiatry
January 2025
Department of Behavioural Science and Health, University College London, London, 1-19 Torrington Place, WC1E 7HB, UK.
Background: Smoking rates in the UK have declined steadily over the past decades, masking considerable inequalities, as little change has been observed among people with a mental health condition. This trial sought to assess the feasibility and acceptability of supplying an electronic cigarette (e-cigarette) starter kit for smoking cessation as an adjunct to usual care for smoking cessation, to smokers with a mental health condition treated in the community, to inform a future effectiveness trial.
Methods: This randomised controlled feasibility trial, conducted March-December 2022, compared the intervention (e-cigarette starter kit with a corresponding information leaflet and demonstration with Very Brief Advice) with a 'usual care' control at 1-month follow-up.
J Gen Intern Med
January 2025
University of Connecticut School of Medicine, Farmington, CT, USA.
NPJ Parkinsons Dis
January 2025
Department of Neuroscience & Experimental Therapeutics, Texas A&M University College of Medicine, 8447 John Sharp Pkwy, Bryan, TX, 77807-3260, USA.
The smoking cessation drug cytisine exerts neuroprotection in substantia nigra pars compacta (SNc) dopaminergic (DA) neurons of female but not male 6-hydroxydopamine (6-OHDA) lesioned parkinsonian mice. To address the important question of whether circulating 17β-estradiol mediates this effect, we employ two mouse models aimed at depleting systemically circulating 17β-estradiol: (i) bilateral ovariectomy (OVX), and (ii) aromatase inhibition with systemically administered letrozole. In both models, depleting systemically circulating 17β-estradiol in female 6-OHDA lesioned parkinsonian mice results in the loss of cytisine-mediated neuroprotection as measured using apomorphine-induced contralateral rotations and SNc DA neurodegeneration.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!